Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Basis of preparation

Basis of preparation
12 Months Ended
Dec. 31, 2021
Basis of preparation


2. Basis of preparation


Statement of Compliance


These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).


Basis of Measurement and Presentation


These consolidated financial statements have been prepared using the historical cost convention except for financial instruments which have been measured at fair value. These consolidated financial statements were prepared on an accrual basis except for cash flow information.






In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. The accounting policies set out below have been applied consistently to all years presented in these consolidated financial statements.


These consolidated financial statements incorporate the financial statements of the Company and its 100% owned subsidiary. The accounts of the Company’s subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated. The Company’s subsidiary is the following:


Name Place of Incorporation Ownership Percentage
XORTX Pharma Corp.




These consolidated financial statements were approved for issue by the Board of Directors on April 7, 2022.